Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (DELAY)

13 novembre 2026 mis à jour par: Fabian Acker, Goethe University

Delayed Application of Immune Checkpoint Inhibitors in Patients With Advanced or Metastatic NSCLC Receiving Chemoimmunotherapy

This study is a multicenter, randomized, open-label phase 3 trial of delayed administration of immunotherapy in patients who are planned to receive chemoimmunotherapy for newly diagnosed, advanced or metastatic, PD-L1 positive NSCLC without sensitizing alterations in EGFR, ALK, or ROS1.

Aperçu de l'étude

Description détaillée

This study enrolls patients with newly diagnosed, PD-L1 positive (PD-L1 TPS ≥ 1%), EGFR/ALK/ROS1-wildtype/-negative, advanced or metastatic non-small cell lung cancer who have not yet received systemic treatment.

Patients are randomized into two treatment arms. In both arms, patients receive standard treatment with histology-guided chemotherapy in combination with the PD-1 inhibitor cemiplimab. Patients in the experimental arm receive chemotherapy on Day 1 and cemiplimab on Day 4 of each cycle. Patients in the control arm receive both therapies on Day 1 of each cycle. After 4 cycles, patients continue with cemiplimab either with or without pemetrexed as per standard of care.

The time interval between chemotherapy and immunotherapy is intended to minimize antagonistic effects of chemotherapy on immunotherapy while simultaneously enhancing potential synergistic effects between the two treatment modalities.

Type d'étude

Interventionnel

Inscription (Estimé)

198

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Hesse
      • Frankfurt am Main, Hesse, Allemagne, 60590
        • Universitätsmedizin Frankfurt
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Provided written informed consent

  2. Patients must be at least 18 years old

  3. Patients with histologically or cytologically confirmed locally advanced (stage IIIB-C per UICC 9th edition) or metastatic (stage IV) non-small cell lung cancer (NSCLC) who are not candidates for treatment in curative intent including resection and/or definitive chemoradiotherapy, and who have received no prior systemic treatment for recurrent or metastatic NSCLC Note: Patients who received systemic therapies as part of a surgical and/or radiotherapeutic treatment with curative intent (including concomitant, neoadjuvant, adjuvant and/or maintenance therapies) and developed recurrent or metastatic disease more than 12 months after completing therapy are eligible

  4. Positive tumor PD-L1 status defined as PD-L1 tumor proportion score ≥1% (local testing)

  5. No sensitizing alterations in EGFR, ALK or ROS1 (local testing)

  6. At least one (measurable) target lesion according to RECIST version 1.1. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site.

  7. Planned treatment with an anti-PD-(L)1 inhibitor plus platinum-based chemotherapy

  8. Adequate organ function

    1. Hemoglobin ≥ 9g/dl, neutrophil count ≥ 1500/mm³, platelets ≥ 100.000/µL
    2. Estimated glomerular filtration rate (GFR) ≥30ml/min/1.73m²
    3. Bilirubin ≤1.5 x ULN, AST and ALT ≤ 3 x ULN Note: in the case of hepatic involvement, the following criteria apply: Bilirubin ≤3 x ULN, AST and ALT ≤ 5 x ULN
  9. The patient is willing and able to comply with the protocol for the duration of the study, including visits for treatment and scheduled follow-up visits and examinations

Exclusion Criteria:

  1. Symptomatic, neurologically unstable CNS metastases or requiring increasing doses of steroids to manage CNS symptoms within 2 weeks prior to study entry (maximal acceptable dose must be ≤10 mg of prednisolone or equivalent).

    Note: Patients with asymptomatic, incidentally detected CNS metastases may be enrolled. Palliative radiotherapy for asymptomatic brain metastases (and any other, non-brain metastases, e.g. bone metastases) may be conducted after study entry.

  2. Patients with leptomeningeal disease or spinal cord compression

  3. Concurrent enrollment in another interventional trial. Participation in observational studies is acceptable

  4. Presence of cardiovascular disease, as defined by:

    1. New York Heart Association (NYHA) heart failure classifications of class III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or
    2. Transient ischemic attack or stroke within 1 year
  5. Patients with a history of another malignancy that is either untreated or was treated within the past 3 years, with the exception of malignancies with a low risk of recurrence, such as adequately treated non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer or ductal carcinoma in situ. Other similar cases can be considered after discussion with the coordinating investigator

  6. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts

  7. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities Exclusion criteria related to autoimmunity, autoinflammation and immunodeficiency

  8. Any condition that requires ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1 week prior to the first dose of study medication. Participants who require a brief course of steroids (up to 2 days in the week before enrollment) or physiologic replacement are not excluded.

  9. Ongoing or recent evidence of significant autoimmune or inflammatory disease that required treatment with systemic immunosuppressive treatments within the last 2 years.

    Note: The following are not exclusionary: non-bullous skin conditions (e.g., vitiligo), endocrinopathies (such as hypothyroidism or type 1 diabetes) that require only hormone replacement. Other similar cases may be eligible upon consultation with the coordinating investigator.

  10. History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis or organizing pneumonia), of active, non-infectious pneumonitis that required immunosuppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is not exclusionary

  11. History of solid organ or hematopoietic stem cell transplantation. Corneal transplantation is not exclusionary Exclusion criteria relating to infections

  12. Uncontrolled infection with HIV, hepatitis B or hepatitis C infection, diagnosis of immunodeficiency, and/or tuberculosis (active or latent)

    a) Participants with known controlled HIV infection (undetectable viral load on HIV RNA PCR) and CD4 count above 350/µl either spontaneously or on a stable antiviral regimen are eligible. For these participants monitoring will be performed per local standards.

    b) Participants with HBsAg positive who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for hepatitis B) are eligible. Participants with controlled infections must undergo periodic monitoring of HBV DNA. Participants must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study medication.

    c) Participants with HBsAg negative but total HBcAb positive are permitted with the following requirements: If serum HBV DNA PCR is above the limit of detection at screening, initiate HBV antiviral therapy before study entry. If serum HBV DNA PCR is below the limit of detection, periodic monitoring of HBsAg must be performed.

    d) Participants who are HCV Ab+ who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are eligible Exclusion criteria relating to vaccines

  13. Receipt of a live vaccine within 4 weeks of start of study medication

  14. Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.

    Exclusion criteria relating to pregnancy and contraception

  15. Women who are pregnant or breast-feeding

  16. WOCBP* and men** who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 4 months after the last dose. Highly effective contraceptive measures include:

    1. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening;

    2. Intrauterine device; intrauterine hormone-releasing system;

    3. Bilateral tubal occlusion/ligation;

    4. Vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and/or

    5. Sexual abstinence†,‡. Pregnancy testing and contraception are required for WOCBP. Pregnancy testing and contraception are not required for women who are postmenopausal or permanently sterile.

      • WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.

      A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to the CTFG guidance. Pregnancy testing and contraception are not required for women with documents hysterectomy or tubal ligation.

      **Male participants: A male participant will be excluded from the study if that participant does not agree to use condoms or practice sexual abstinence†‡, unless vasectomized, prior to the initial dose/start of study medication, during the study, and for at least 4 months after the last dose. Sperm donation is also prohibited during the same period. Vasectomy success must be confirmed by semen analysis.

      †Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drugs. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.

      ‡Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Delayed Chemoimmunotherapy

4 courses of cisplatin/carboplatin D1 + pemetrexed/paclitaxel D1 + cemiplimab D4 every 3 weeks, followed by maintenance cemiplimab ± pemetrexed

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Comparateur actif: Concurrent Chemoimmunotherapy

4 courses of cisplatin/carboplatin D1 + pemetrexed/paclitaxel D1 + cemiplimab D1 every 3 weeks, followed by maintenance cemiplimab ± pemetrexed

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
PFS
Délai: max. 60 months

Progression-free survival (PFS), defined as time from randomization until the first documented progression per investigator-assessed RECIST 1.1 criteria or death due to any cause, whichever occurs first

max. 60 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
ORR
Délai: max. 60 months

Objective response rate (ORR) is defined as the number of patients achieving a complete or partial response per investigator-assessed RECIST 1.1 criteria as best overall response divided by the number of patients

max. 60 months
OS
Délai: max. 60 months

Overall survival (OS) is defined as the time from randomization to the date of death due to any cause

max. 60 months
DOR
Délai: max. 60 months

Duration of response per investigator-assessed RECIST 1.1 is defined as the time between the first detection of complete or partial response, whichever occurs earlier, and disease progression or death. DOR will be calculated in patients who achieve a complete or partial response.

max. 60 months
DCR
Délai: max. 60 months

Disease control rate (DCR) is defined as the number of patients achieving a complete or partial response or stable disease per investigator-assessed RECIST 1.1 criteria divided by the number of patients

max. 60 months
Frequency and severity of immune-related adverse events (irAEs)
Délai: max. 60 months
max. 60 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Fabian Acker, Dr., Goethe University Frankfurt, University Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 février 2027

Achèvement primaire (Estimé)

1 février 2032

Achèvement de l'étude (Estimé)

1 février 2032

Dates d'inscription aux études

Première soumission

9 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner